<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322656</url>
  </required_header>
  <id_info>
    <org_study_id>LPF</org_study_id>
    <nct_id>NCT04322656</nct_id>
  </id_info>
  <brief_title>Stability of Biometry in Meibomian Gland Dysfunction</brief_title>
  <official_title>Stability of Biometry in Patients With Meibomian Gland Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vienna Institute for Research in Ocular Surgery</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vienna Institute for Research in Ocular Surgery</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Accurate biometry is an essential and indispensable tool in preoperative cataract surgery
      setting to yield optimal postoperative refractive outcome. However, some recent studies
      indicate that preoperative biometry is influenced by dry eye disease (DED). Hence, the
      investigator's study aims to investigate the effect of the therapy of MGD using the Lipiflow®
      device on the stability of biometry and selection of IOL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Accurate biometry is an essential and indispensable tool in preoperative cataract surgery
      setting to yield optimal postoperative refractive outcome. 31 Patients suffering from DED
      caused by MGD will be selected and allocated randomly to therapy. Patients with pre-existing
      DED therapy other than lubricants will be excluded. After completing prestudy-screening and
      baseline visit, Lipiflow® therapy is applied to the study eye. Follow-up visits will be
      scheduled two weeks and three months after baseline visit. Each visit includes dry eye
      investigations and IOL calculation by IOLmaster 700 and CSO MS-39. After each study visit an
      IOL will be theoretically selected.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spherical and toric IOL power selected at baseline and at 3 months visit</measure>
    <time_frame>12 months</time_frame>
    <description>The difference between pre- and post-treatment biometrical calculated IOL power will be calculated and compared</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Dry Eye Syndrome Caused by Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>Effect of Lipiflow treatment on biometrical outcomes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One eye of each patient will be treated with Lipiflow</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control eye</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The contralateral eye will serve as control eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lipiflow treatment</intervention_name>
    <description>Patients will be treated on one eye with Lipiflow</description>
    <arm_group_label>Effect of Lipiflow treatment on biometrical outcomes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age older than 18 years

          -  Evidence of meibomian gland dysfunction

          -  Meibomian gland secretion score equal or less than 15 (for 15 glands of the lower eye
             lid) using the meibomian gland evaluator (see below)

        Exclusion Criteria:

          -  Usage of eye drops other than lubricants (e.g. antibiotics, steroids, cyclosporin-A)

          -  Usage of systemic antibiotic therapy

          -  Any pathology of the ocular surface except dry eye disease (e.g. corneal scarring,
             cornea ectasia)

          -  Ocular surgery within prior 3 months

          -  Ocular injury within prior 3 months

          -  Ocular herpes of eye or eyelid within prior 3 months

          -  Active ocular infection

          -  Active ocular inflammation or history of chronic, recurrent ocular inflammation within
             prior 3 months

          -  Eyelid abnormalities that affect lid function

          -  Ocular surface abnormality that may compromise corneal integrity

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oliver Findl, Univ.Prof. Dr.</last_name>
    <phone>+43 1 91021-84611</phone>
    <email>oliver@findl.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan Palkovits, Priv.Doz. Dr.</last_name>
    <phone>+43 1 91021-84611</phone>
    <email>spalkovits@viros.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vienna Institute for Research in Ocular Surgery</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Findl, Univ.Prof. Dr.</last_name>
      <phone>+43 1 91021-84611</phone>
      <email>oliver@findl.at</email>
    </contact>
    <investigator>
      <last_name>Stefan Palkovits, Priv.Doz. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oliver Findl, Univ.Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vienna Institute for Research in Ocular Surgery</investigator_affiliation>
    <investigator_full_name>Prim. Prof. Dr. Oliver Findl, MBA</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lipiflow</keyword>
  <keyword>Meibomian gland dysfunction</keyword>
  <keyword>Biometry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

